A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

When is the best time to start your anti-ageing treatments? Doctors at Bay Aesthetics Clinic weigh in. Read more at ...

After the surgery, she received a year’s treatment with the anticancer drug trastuzumab. Stephen Russell, an OVT specialist ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China - ...

Physicians may be able to achieve the same type of treatment effect without repeated injections into the eye at the same frequency that we do them now. We may be able to do that with a safety profile ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

PARIS, France and TARRYTOWN, NY, USA I 6, 2024 I The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis ...

Johnson & Johnson announced that the China National Medical Products Administration has approved Teclistamab Injection as a ...

A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...